Vasoproliferation and Antiproliferative Treatment Options in Pulmonary Arterial Hypertension

Author(s): Markus Blaukovitsch, Peter Zabel, Hans-Peter Hauber

Journal Name: Recent Patents on Cardiovascular Drug Discovery
Continued as Recent Advances in Cardiovascular Drug Discovery

Volume 4 , Issue 2 , 2009


New treatment options have improved the prognosis of patients with pulmonary arterial hypertension. However, drugs such as prostanoids, PDE5 inhibitors and endothelin receptor antagonists mainly act as vasodilating agents. Recently, it has become clear that pulmonary arterial hypertension is an inflammatory and vasoproliferative disease. Therefore new anti-inflammatory and antiproliferative treatments are needed. This review will focus on the pathogenesis of inflammation and vasoproliferation in pulmonary hypertension. In addition, an overview on possible new antiinflammatory and antiproliferative drugs in pulmonary hypertension (e.g. Rho-kinase inhibitors, imatinib mesylate. HMG-CoA reductase inhibitors) will be given along with recent patents.

Keywords: Endothelin, inflammation, inhibitor, kinase, proliferation, prostanoid, pulmonary hypertension, Rho, &, serotonin

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Published on: 01 March, 2012
Page: [142 - 149]
Pages: 8
DOI: 10.2174/157489009788452968
Price: $65

Article Metrics

PDF: 2